pharmaphorum

SEPTEMBER 14, 2020

Here he gives us a deeper look at how genomic medicine is evolving and the barriers that are preventing it from reaching its full potential. I saw this, in particular, with the finishing of the human genome,” says Charlie. “At In reality, finishing the human genome was the first step of what is a long journey.”.

Genomics 119

Genomics Genome Medicine Gene 119

XTalks

DECEMBER 14, 2022

Developed by MIT researchers Jonathan Gootenberg and Omar Abudayyeh, PASTE (Programmable Addition via Site-specific Targeting Elements) gene editing technology can insert genes as long as 36,000 DNA base pairs to liver cells in mice as well as several types of human cells.

Gene Editing 98

Gene Editing DNA Gene Gene Sequencing 98

Scienmag

JUNE 21, 2022

HOUSTON – (June 21, 2022) – It’s a given that certain bacteria and viruses can cause illness and disease, but the real culprits are the sequences of concern that lie within the genomes of these microbes. Credit: Treangen Lab/Rice University HOUSTON – (June 21, 2022) – It’s a given that certain bacteria and viruses can […].

DNA 62

DNA Bacteria Genome Genomics 62

The Pharma Data

OCTOBER 19, 2020

By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through the Caris Molecular Intelligence® platform, physicians from Winship will be able to further prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients.

Life Science 52

Life Science Clinical Trials Clinical Trials RNA 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. CRISPR nucleases serve as an important genome editing tool.

In-Vivo 162

In-Vivo Genome Genomics Gene Editing 162

The Pharma Data

OCTOBER 14, 2020

ERS Genomics – Ireland’s ERS Genomics signed an agreement with FASMAC Co., Patent and Trademark Office that covers peptides from the company’s two peptide classes and their use in the treatment of diabetes and its complications. The patent is valid through 2038. Ltd of Japan. million if certain project milestones are met.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing In-Vivo 52

The Pharma Data

SEPTEMBER 28, 2021

Respiratory infections are caused by a good sort of pathogens, like influenza viruses, respiratory syncytial virus, parainfluenza viruses, metapneumovirus, rhinovirus, enterovirus, coronavirus and adenovirus, and other bacteria pathogens. Source link: [link].

Marketing 52

Marketing In-Vitro DNA Bacteria 52